Repros Therapeutics Holds Meeting With FDA To Discuss Oral Proellex, FDA Confirms That Proellex To Remain On Partial Clinical Hold While They Consult With Liver Experts Within FDA Regarding Previously Disclosed Effects
Paul Quintaro